Lei Meng

Lei Meng is currently a Board Observer at Quanta Therapeutics, a role he has held since May 2023. He is based in South San Francisco, California, and has a strong background in the biopharmaceutical industry.

Professional Background

• Current Position:
  • Board Observer at Quanta Therapeutics (May 2023 - Present)
• Other Roles:
  • Board Member at Prellis Biologics (August 2022 - Present)
  • Board Member at Dianthus Therapeutics, Inc. (May 2022 - Present)
  • Senior Therapeutics Analyst at Avidity Partners (January 2021 - Present)
• Previous Experience:
  • Vice President, Marketing Analytics and BD&L Commercial Assessments at Allergan, plc (March 2012 - January 2021)
  • Healthcare Analyst at Samlyn Capital, LLC (September 2008 - January 2012)
  • Senior Manager at Forest Laboratories (January 2006 - August 2008)
  • Senior Consultant at McKinsey & Co (March 2004 - January 2006)
  • Clinical Research Scientist at Merck & Co (November 1997 - December 2002)

Education

• Barnard College: BA in Biochemistry (1990 - 1994)
• Harvard University: MA in Chemistry (1994 - 1997)
• INSEAD: MBA (2003)
• Beijing University: Attended

Languages

• Chinese (native or bilingual proficiency)
• French (professional working proficiency)

Lei Meng's extensive experience in the biopharmaceutical sector, particularly in strategic roles involving commercial assessments and board governance, positions him as a significant contributor to Quanta Therapeutics and its mission in developing targeted therapies for RAS-driven cancers.12